Needham analyst David Saxon has maintained their neutral stance on XRAY stock, giving a Hold rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
David Saxon has given his Hold rating due to a combination of factors surrounding DENTSPLY SIRONA’s recent performance and future outlook. The company’s revenue for the third quarter of 2025 exceeded expectations, but its earnings per share fell short of predictions, prompting management to revise its growth and earnings guidance downward.
Despite these challenges, DENTSPLY SIRONA is making strategic investments in areas such as research and development and commercial operations, which are expected to foster growth in the long term. Management is optimistic about returning to profitable growth within the next two years, with 2026 anticipated as a pivotal transition year and 2027 potentially reaping the benefits of these initiatives. While the company’s strategic direction is promising, the anticipated timeline for a turnaround suggests a gradual process, leading to the decision to maintain a Hold rating.
In another report released today, Stifel Nicolaus also reiterated a Hold rating on the stock with a $13.00 price target.